Nottegar Alessia, Tabbò Fabrizio, Luchini Claudio, Brunelli Matteo, Bria Emilio, Veronese Nicola, Santo Antonio, Cingarlini Sara, Gilioli Eliana, Ogliosi Chiara, Eccher Albino, Montagna Licia, Pedron Serena, Doglioni Claudio, Cangi Maria G, Inghirami Giorgio, Chilosi Marco
Department of Diagnostics and Public Health.
Department of Molecular Biotechnology and Health Science, Center for Experimental Research and Medical Studies (CeRMS), University of Turin, Turin.
Appl Immunohistochem Mol Morphol. 2018 Jul;26(6):383-387. doi: 10.1097/PAI.0000000000000440.
Pulmonary adenocarcinoma with enteric differentiation (PAED) is a rare subtype of lung adenocarcinoma recently recognized in the WHO classification. It is defined as an adenocarcinoma in which the enteric component exceeds 50% and have to show the expression of at least 1 immunohistochemical marker of enteric differentiation. Although the definition of this tumor type is very important, above all in the differential diagnosis between a primary lung tumor and a metastasis of colorectal adenocarcinoma, this cancer still lacks a distinctive immunohistochemical and molecular signature. We recruited the largest series in the literature of PAEDs according to the morphology and the positivity for intestinal markers. Then, we evaluated the immunohistochemical and molecular profile of these adenocarcinomas. In our series, CDX-2 and CK7 were the immunohistochemical markers mostly expressed by PAEDs. There was an inverse relationship between the expression of pnuemocytes markers, such as TTF-1, and intestinal markers. Molecular analysis revealed KRAS as the most frequently mutated gene (>60% of cases), with very few cases harboring abnormalities affecting EGFR, BRAF, and ALK genes. PAEDs are morphologically very heterogenous. The immunohistochemical profile based on CDX-2 and CK7 positivity of PAEDs appears very robust to support this diagnosis, and it is applicable also on small biopsies. KRAS appears as the most important mutated gene in such tumors.
具有肠化生的肺腺癌(PAED)是世界卫生组织分类中最近才确认的一种罕见的肺腺癌亚型。它被定义为肠化生成分超过50%且必须显示至少一种肠化生免疫组化标志物表达的腺癌。尽管这种肿瘤类型的定义非常重要,尤其是在原发性肺肿瘤与结直肠癌转移瘤的鉴别诊断中,但这种癌症仍缺乏独特的免疫组化和分子特征。我们根据形态学和肠道标志物阳性情况,收集了文献中最大系列的PAED病例。然后,我们评估了这些腺癌的免疫组化和分子特征。在我们的病例系列中,CDX-2和CK7是PAED最常表达的免疫组化标志物。肺上皮细胞标志物(如TTF-1)的表达与肠道标志物的表达呈负相关。分子分析显示KRAS是最常发生突变的基因(>60%的病例),只有极少数病例存在影响EGFR、BRAF和ALK基因的异常。PAED在形态学上非常异质性。基于PAED的CDX-2和CK7阳性的免疫组化特征似乎对支持这一诊断非常可靠,并且也适用于小活检标本。KRAS似乎是这类肿瘤中最重要的突变基因。